Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway

Huang,Haili; Hu,Min; Zhao,Rui; Li,Peng; Li,Mingyi

doi:10.3892/or.2013.2705

Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway

Authors:
- Haili Huang
- Min Hu
- Rui Zhao
- Peng Li
- Mingyi Li
View Affiliations

Affiliations: Laboratory of Hepatobiliary Surgery, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China, Institute of Gene Engineering, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Clinical Research Center, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
Published online on: August 29, 2013 https://doi.org/10.3892/or.2013.2705
Pages: 2467-2475

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the antitumor mechanism of dihydromyricetin (DHM). Results showed that DHM significantly inhibited cell viability of HepG2 and Hep3B cells in a dose-dependent manner. DHM induced G2/M cell-cycle arrest in HepG2 and Hep3B cells by altering the expression of cell cycle proteins such as cyclin A, cyclin B1, Cdk1, p53, Cdc25c, p-Cdc25c Chk1 and Chk, which are critical for G2/M transition. Knockdown of p53 and Chk1 in HepG2 cells did not affect G2/M phase arrest caused by DHM. Furthermore, G2/M arrest induced by DHM can be disrupted by Chk2 siRNA. These findings indicate that DHM inhibits the growth of hepatocellular carcinoma (HCC) cells via G2/M phase cell cycle arrest through Chk1/Chk2/Cdc25C pathway. The present study identified effects of DHM in G2/M phase arrest in HCC and described detailed mechanisms of G2/M phase arrest by this agent, which may contribute to its overall cancer preventive efficacy in HCC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
2	Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
3	Huang WW, Ko SW, Tsai HY, et al: Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways. Int J Oncol. 38:1067–1073. 2011.
4	Visanji JM, Thompson DG and Padfield PJ: Induction of G2/M phase cell cycle arrest by carnosol and carnosic acid is associated with alteration of cyclin A and cyclin B1 levels. Cancer Lett. 237:130–136. 2006. View Article : Google Scholar : PubMed/NCBI
5	Parker LL and Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 257:1955–1957. 1992. View Article : Google Scholar : PubMed/NCBI
6	Ruiz EJ, Vilar M and Nebreda AR: A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. Curr Biol. 20:717–723. 2010. View Article : Google Scholar : PubMed/NCBI
7	Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1501–1505. 1997. View Article : Google Scholar : PubMed/NCBI
8	Ahn J and Prives C: Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J Biol Chem. 277:48418–48426. 2002. View Article : Google Scholar : PubMed/NCBI
9	Turowski P, Franckhauser C, Morris MC, Vaglio P, Fernandez A and Lamb NJ: Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell. 14:2984–2998. 2003. View Article : Google Scholar : PubMed/NCBI
10	Choi YH, Lee WH, Park KY and Zhang L: p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res. 91:164–173. 2000. View Article : Google Scholar : PubMed/NCBI
11	Rief N, Herges H, Prowald A, Gotz C and Montenarh M: Binding of the growth suppressor p53 protein to the cell cycle regulator phosphatase cdc25C. Int J Oncol. 17:189–195. 2000.PubMed/NCBI
12	St Clair S, Giono L, Varmeh-Ziaie S, et al: DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell. 16:725–736. 2004.PubMed/NCBI
13	Hirao A, Kong YY, Matsuoka S, et al: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
14	Ye R, Bodero A, Zhou BB, Khanna KK, Lavin MF and Lees-Miller SP: The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. J Biol Chem. 276:4828–4833. 2001. View Article : Google Scholar : PubMed/NCBI
15	Canman CE, Lim DS, Cimprich KA, et al: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1677–1679. 1998. View Article : Google Scholar : PubMed/NCBI
16	Banin S, Moyal L, Shieh S, et al: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI
17	Dalal SN, Schweitzer CM, Gan J and DeCaprio JA: Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol. 19:4465–4479. 1999.PubMed/NCBI
18	Graves PR, Lovly CM, Uy GL and Piwnica-Worms H: Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 20:1839–1851. 2001. View Article : Google Scholar : PubMed/NCBI
19	Savitsky PA and Finkel T: Redox regulation of Cdc25C. J Biol Chem. 277:20535–20540. 2002. View Article : Google Scholar : PubMed/NCBI
20	Bulavin DV, Demidenko ZN, Phillips C, Moody SA and Fornace AJ Jr: Phosphorylation of Xenopus Cdc25C at Ser285 interferes with ability to activate a DNA damage replication checkpoint in pre-midblastula embryos. Cell Cycle. 2:263–266. 2003. View Article : Google Scholar : PubMed/NCBI
21	Perdiguero E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle. 3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
22	Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA and Agarwal R: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis. 26:1978–1987. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zeng S, Luo GQ and Liu DY: The chemotaxis effect of ampelopsin on the immunocytes. Zhong Yao Cai. 29:260–262. 2006.(In Chinese).
24	He G, Du F, Yang W, Pei G and Zhu Y: Effects of tengcha flavonoids on scavenging oxygen free radicals and inhibiting lipid-peroxidation. Zhong Yao Cai. 26:338–340. 2003.(In Chinese).
25	Murakami T, Miyakoshi M, Araho D, et al: Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. Biofactors. 21:175–178. 2004. View Article : Google Scholar : PubMed/NCBI
26	Ni F, Gong Y, Li L, Abdolmaleky HM and Zhou JR: Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One. 7:e388022012. View Article : Google Scholar : PubMed/NCBI
27	Zeng S, Liu D, Ye Y, Wang L and Wang W: Antitumor effects of ampelopsin on human lung cancer GLC-82 implanted in nude mice. Zhong Yao Cai. 27:842–845. 2004.(In Chinese).
28	Liu D and Luo M: Study on inhibitory effect of ampelopsin on melanoma by serologic pharmacological method. Zhong Yao Cai. 24:348–350. 2001.(In Chinese).
29	Liu DY, Zheng HQ and Luo GQ: Effects of ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo and in vitro. Zhongguo Zhong Yao Za Zhi. 28:957–961. 2003.(In Chinese).
30	Luo GQ, Zeng S and Liu DY: Inhibitory effects of ampelopsin on angiogenesis. Zhong Yao Cai. 29:146–150. 2006.(In Chinese).
31	Ye J, Zheng Y and Liu D: Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. Zhongguo Zhong Yao Za Zhi. 34:761–765. 2009.(In Chinese).
32	Nurse P: Universal control mechanism regulating onset of M-phase. Nature. 344:503–508. 1990. View Article : Google Scholar : PubMed/NCBI
33	Zhong ZX, Qin JP, Zhou GF and Chen XF: Experimental studies of hypoglycemic action on total flavone of Ampelopsis grossedentata from Guangxi. Zhongguo Zhong Yao Za Zhi. 27:687–689. 2002.(In Chinese).
34	Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol. 15:2600–2611. 1995.PubMed/NCBI
35	Wang Z, Xie Y, Zhang L, et al: Migratory localization of cyclin D2-Cdk4 complex suggests a spatial regulation of the G1-S transition. Cell Struct Funct. 33:171–183. 2008. View Article : Google Scholar : PubMed/NCBI
36	Goldstone S, Pavey S, Forrest A, Sinnamon J and Gabrielli B: Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene. 20:921–932. 2001. View Article : Google Scholar : PubMed/NCBI
37	Galaktionov K, Lee AK, Eckstein J, et al: CDC25 phosphatases as potential human oncogenes. Science. 269:1575–1577. 1995. View Article : Google Scholar : PubMed/NCBI
38	Karlsson C, Katich S, Hagting A, Hoffmann I and Pines J: Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol. 146:573–584. 1999. View Article : Google Scholar : PubMed/NCBI
39	Li J and Stern DF: Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem. 280:12041–12050. 2005. View Article : Google Scholar : PubMed/NCBI
40	Peng A and Chen PL: NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage. J Biol Chem. 278:8873–8876. 2003. View Article : Google Scholar : PubMed/NCBI